Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • IIAR
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • IIAR
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with 153Samarium-EDTMP

HELMUT SINZINGER, KONRAD WEISS and JUKKA HILTUNEN
Anticancer Research August 2009, 29 (8) 3393-3395;
HELMUT SINZINGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: helmut.sinzinger@chello.at
KONRAD WEISS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUKKA HILTUNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

153Samarium-ethylendiaminetetramethylenephosphonate (EDTMP) has become a treatment of choice for painful bone recurrences. The reasons and the background of the Vienna protocol in 1994 are outlined. A 30 mCi (1.1 GBq) dose exhibits comparable pain palliation with less hematotoxicity as compared to 1 mCi/kg, the conventional dose widely used, the 3 months interval as most of the patients (around 80%) show pain palliation for that period of time. Repeated administration furthermore allows lesion stabilization/regression and a tumor marker response. Other reasons are outlined in detail. The earlier 153Sm-EDTMP is started the better; patients not only experience effective bone pain palliation, but also improved quality of life, lesion stabilization/regression and a prolonged survival.

  • Bone recurrences
  • Vienna protocol
  • 153Sm-EDTMP

Up to 75% of patients suffering from prostate, breast or lung cancer go on to develop bone recurrences. Radionuclide therapy has been introduced for bone pain palliation using strontium-89, replaced later by rhenium (186Re) and samarium (153Sm). Originally directed at bone pain palliation treatment in final disease stages only, a variety of therapeutic schedules for 153Sm-ethylendiaminetetramethylenephosphonate (EDTMP) has been used. Based on experimental data, Turner et al. were the first to propose the benefits of repeated treatment (1), a suggestion which has not been followed for quite a long time. This paper aims to explain why the Vienna protocol (2) was chosen to optimize the benefits of 153Sm-EDTMP.

Methods and Results

When 153Sa-EDTMP was introduced into bone pain palliation it fast became evident that the strategy ‘the sooner, the better’ is preferable. Based upon the finding that a dose of 1 mCi/kg is not more beneficial (Table I) as compared to 0.5 mCi/kg (we generally use 30 mCi) concerning bone pain palliation (Table II) but does significantly more affect the bone marrow, in 1994 we started to treat patients according to the Vienna protocol (Table III) for the first time based on repeated treatments (Table IV) on a given schedule (3). Contraindication for the treatment is a platelet count <100.103/μl, a white blood cell count <3.103/μl and a red blood cell count <3.106/μl, hematocrit <30% and hemoglobin <12 g/l. However, if an abnormally low blood cell count is due to bone marrow suppression by tumor cell infiltration, a beneficial response and even an increase in peripheral blood cell count after therapy has been seen (4). Platelets are most affected by 153Sm-EDTMP treatment followed by white and red blood cells. Usually, within 3 months (mainly between weeks 10 and 12) the peripheral blood cell count almost completely returns to the pre-values.

Therapy is performed 5 times at 3-month intervals (Table V), followed by 6-, 9- and 12- month intervals with 5 treatments each. The respective treatment intervals are shortened in case of proven disease progression (scintigraphy, magnetic resonance imaging (MRI)). Blood cell count is performed 3 and 6 weeks after therapy as well as immediately before the next scheduled one. Treatment is already indicated when more than 1 bone lesion and/or bone pains exist (Table VI) on an outpatient base (Table VII).

Repeated application clearly shows benefits beyond pain palliation such as tumor marker decrease and lesion regression, as monitored and proven by various imaging techniques (scintigraphy, MRI) (5, 6) (Figure 1 A-C). Prostate-specific antigen (PSA) after a few weeks may show a temporary increase, while in the majority of the patients (71%) it decreased after 3 months. Older bone lesions show a better therapeutic response as compared to new ones appearing after first therapy (Table VIII). As yet, however, there is no individual predictor of response available. While the interindividual 153Sm-EDTMP uptake varies greatly (~ 30% up to ~90%), the intraindividual one is rather stable (<7% deviation). Concomitant or even repeated application of biphosphonates does not significantly affect the uptake. Bone uptake does not correlate with treatment response. This indicates that pretherapeutic dosimetry is of low prospective value. A significant improvement in quality of life, pain score, Karnofsky score, WHO questionnaire results and reduction of analgesic consumption has been documented.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Pain response upon 153Sm-EDTMP (in %).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Why 30 mCi?

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

The Vienna protocol: 30 mCi (1.1 GBq) 153Sm-EDTMP repeatedly intravenously.

Discussion

Samarium uptake in bone lesions has been shown to be identical to that by conventional technetium-99m diagnostic bone scintigraphy. 99mTc-EDTMP uptake studies do not provide any benefit, and the quality of data is poorer as compared to methylenediphosphonate (MDP) and others.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Why repeated treatment?

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Why 3 months?

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Inclusion criteria for 153Sm-EDTMP

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VII.

Why on an outpatient basis?

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VIII.

Therapeutic response to 30 mCi 153Sm-EDTMP.

153Sm-EDTMP uptake studies may cause stunning (i.e. reduced uptake of second radionuclide dose) if carried out within a few days before scheduled treatment (unpublished data). As uptake does not correlate to therapeutic benefit, pretherapeutic dosimetry offers no advantage to the patient.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Example of lesion regression in a 74-year-old male suffering from prostate cancer. Images from A) 1st therapy (28.3.2003): two hot spots in the vertebral column verified by (MRI) reflect recurrences; B) after 5 treatments (28.4.2004), the 2 abnormal uptake sites in the vertebral column are no longer visible; C) MDP-scintigraphy (26.1.2006), still no sign of recurrences in the skeletal system.

Conclusion

Early and repeated 153Sm-EDTMP is the key to improved therapeutic benefit in patients with painful bone recurrences.

153Sm-EDTMP reduces bone pain, increases quality of life, diminishes lesion sites, tumor markers and tumor indicators and improves survival. Chances for regression of early-stage old lesions are significantly better as compared to new ones showing up during therapy. Concomitant chemotherapy indicates improved benefit (7). Even osteoclastic lesions beneficially respond to 153Sm-EDTMP as far as they show up positively on bone scintigraphy.

The role of 153Sm-EDTMP therapy in micrometastases still remains unclear. There is some reason to believe that concomitant statin treatment improves the benefit, as do a higher pretherapeutic red blood cell count and higher hemoglobin. Samarium, the sooner, the better, should be used. This approach is prior to conventional therapeutic schemes.

There are still a variety of open questions to be answered as to how histology, stage of the disease, osteoblastic versus osteoclastic lesions, the intervals, the number of treatments, concomitant (chemotherapeutic and statin) treatment, type and intensity, the level of hemoglobin (erythropoietin), sensitization, stunning, and many others might all influence the final therapeutic outcome (8).

Prospective studies should assess the benefit of this therapeutic regimen. Even later-stage surgery of 153Sm-EDTMP-treated prostate cancer patients might provocatively be considered in the future.

Footnotes

  • Part of the data was presented at the 8th International Conference Anticancer Research, Kos, Greece, in October 2008.

  • Received April 21, 2009.
  • Revision received June 2, 2009.
  • Accepted June 9, 2009.
  • Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Turner JH,
    2. Martindale A,
    3. Sorby P,
    4. Hetgerington EL,
    5. Fleay RF,
    6. Hoffmann RF,
    7. Claringbold PG
    : Samarium 153-EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 15: 784-795, 1989.
    OpenUrlPubMed
  2. ↵
    1. Sinzinger H,
    2. Ofluoglu S,
    3. Granegger S
    : Behaviour of prostate specific antigen after 153Sm-EDTMP therapy (Vienna Protocol). Europ J Nucl Med and Molec Imaging 30: 338, 2003.
    OpenUrl
  3. ↵
    1. Sinzinger H,
    2. Kratzik C,
    3. Zielinski C
    : 153Samarium-EDTMP-pain palliation and effects beyond. Europ J Nucl Med 27: 86, 2000.
    OpenUrl
  4. ↵
    1. Sinzinger H,
    2. Palumbo B,
    3. Kratzik C,
    4. Chehne F,
    5. Palumbo R
    : Bone marrow suppression by tumor infiltration - a (contra-) indication for 153Sm-EDTMP therapy in prostate cancer? Eur J Nucl Med 29: 132, 2002.
    OpenUrl
  5. ↵
    1. Sinzinger H,
    2. Palumbo B,
    3. Granegger S,
    4. Kratzik C,
    5. Palumbo R,
    6. Hiltunen J
    : Repeated low-dose Sm-153-EDTMP therapy using the Vienna protocol is effective in pain palliation and lesion regression. J Nucl Med 49: 369, 2008.
    OpenUrl
  6. ↵
    1. Sinzinger H,
    2. Weiss K,
    3. Granegger S
    : Significant regression of bone recurrences secondary to prostate cancer induced by repeated 153Sm-EDTMP. Hell J Nucl Med 6: 94-96, 2003.
    OpenUrl
  7. ↵
    1. Suttmann H,
    2. Grgic A,
    3. Lehmann J,
    4. Zwergel U,
    5. Ramvadt J,
    6. Gouverneur E,
    7. Pinkert J,
    8. Stöckle M,
    9. Kirsch CM,
    10. Nestle U
    : Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm 23: 609-618, 2008.
    OpenUrlPubMed
  8. ↵
    1. Sartor O
    : Overview of Samarium. 153Sm lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6: 3-12, 2004.
    OpenUrl
View Abstract
PreviousNext
Back to top

In this issue

Anticancer Research: 29 (8)
Anticancer Research
Vol. 29, Issue 8
August 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with 153Samarium-EDTMP
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with 153Samarium-EDTMP
HELMUT SINZINGER, KONRAD WEISS, JUKKA HILTUNEN
Anticancer Research Aug 2009, 29 (8) 3393-3395;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Background, Reasons and Benefits Using the Vienna Protocol for the Treatment of Painful Bone Recurrences with 153Samarium-EDTMP
HELMUT SINZINGER, KONRAD WEISS, JUKKA HILTUNEN
Anticancer Research Aug 2009, 29 (8) 3393-3395;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods and Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Evaluation of the Malignant Characteristics of Conjunctival Lesions Based on the Dermatoscopic Algorithm
  • Serological Biomarker Test (GastroPanel®) in the Diagnosis of Functional Gastric Disorders, Helicobacter pylori and Atrophic Gastritis in Patients Examined for Dyspeptic Symptoms
  • Potential Risk Factors Influencing the Formation of Postoperative Seroma After Breast Surgery – A Prospective Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2021 Anticancer Research

Powered by HighWire